dapsone has been researched along with Pneumonia, Pneumocystis in 215 studies
Pneumonia, Pneumocystis: A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/or CD4 lymphocyte counts of < 200/microL were randomized to receive dapsone/pyrimethamine (200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks)." | 9.08 | Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. ( Heald, A; Hirschel, B; Iten, A; Lazzarin, A; Oertle, D; Opravil, M; Pechère, M; Praz, G; Rüttimann, S; von Overbeck, J, 1995) |
| "To examine the interaction between dapsone and trimethoprim in patients with the acquired immunodeficiency syndrome (AIDS)." | 9.06 | Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. ( Benowitz, NL; Jacob, P; Lee, BL; Medina, I; Mills, J; Wofsy, CB, 1989) |
| "To report a case of methemoglobinemia in a patient receiving dapsone for prophylaxis of Pneumocystis carinii pneumonia (PCP)." | 8.80 | Dapsone-induced methemoglobinemia. ( McCarthy, MW; Ward, KE, 1998) |
| "Diaphenylsulfone (DDS: Dapsone) is used for Pneumocystis pneumonia (PCP) prophylaxis, and methemoglobinemia has rarely been reported as a side effect of DDS." | 7.81 | Identifying the Cause of the "Saturation Gap": Two Cases of Dapsone-induced Methemoglobinemia. ( Arita, M; Furuta, K; Hashimoto, T; Ikeda, S; Ikeo, S; Ishida, T; Ito, A; Nishiyama, A; Tachibana, H; Takaiwa, T; Tanaka, M; Tokioka, F; Yokoyama, T; Yoshioka, H, 2015) |
| "Among 167 pediatric patients treated for hematologic malignancies or aplastic anemia who received dapsone for PCP prophylaxis, demographic and dapsone treatment data were retrospectively collected." | 7.77 | Dapsone-induced methemoglobinemia: a dose-related occurrence? ( Esbenshade, AJ; Friedman, DL; Ho, RH; Shintani, A; Smith, LA; Zhao, Z, 2011) |
| "We studied 15 children with acute lymphoblastic leukemia (ALL) receiving dapsone for PCP prophylaxis to determine the frequency of methemoglobinemia, and correlate its occurrence with cytochrome b5 reductase (Cb5R) enzyme levels." | 7.73 | Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. ( Athale, UH; Barr, RD; Hoyer, JD; MacDonald, P; Williams, S, 2005) |
| "This report describes a case of methemoglobinemia in association with dapsone therapy." | 7.73 | Methemoglobinemia associated with dapsone therapy in a child with pneumonia and chronic immune thrombocytopenic purpura. ( Roberts, WD; Schiff, DE; Sue, YJ, 2006) |
| "A 34-year-old woman with HIV infection and no other opportunistic infections presented a classic sulfone syndrome, manifested by fever, rash, hemolytic anemia, and fulminant hepatitis due to dapsone hypersensitive reaction, with a fatal outcome." | 7.69 | Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient. ( Baffoe-Bonnie, H; Chalasani, P; Jurado, RL, 1994) |
| "The efficacy, toxicity and cost of orally administered dapsone (50-100 mg/day) for prophylaxis of Pneumocystis carinii pneumonia (PCP) were evaluated in 30 patients with AIDS or AIDS-related complex (ARC)." | 7.68 | Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. ( Deresinski, SC; Greene, SI; Kemper, CA; Kessinger, JM; Lang, OS; Stevens, DA; Tucker, RM, 1990) |
| "All patients with the acquired immunodeficiency syndrome treated for their first episode of Pneumocystis carinii pneumonia at San Francisco General Hospital between 1 April 1985 and 15 July 1985 were evaluated for their response to treatment with dapsone (100 mg/day) by mouth for 21 days." | 7.67 | Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, WT; Leoung, G; Medina, I; Mills, J; Wofsy, C, 1988) |
| "All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight X d)." | 7.67 | Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, W; Leoung, GS; Mills, J; Wofsy, C, 1986) |
| "In patients with AIDS, oral therapy with trimethoprim-sulfamethoxazole and with trimethoprim-dapsone are equally effective for mild-to-moderate first episodes of P." | 6.67 | Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. ( Benowitz, N; Hopewell, PC; Lee, B; Leoung, G; Medina, I; Mills, J; Modin, G; Wofsy, CB, 1990) |
| "Dapsone was more effective in the primary prophylaxis of toxoplasmic encephalitis, with six toxoplasmic encephalitis events occurring among those receiving aerosolized pentamidine, compared to none among those taking dapsone (p = 0." | 6.67 | Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. ( Barr, M; Carlo, C; Chanin, E; Gregory, G; Kiely, S; Martin, M; Thorn, M; Thornton, J; Torres, RA, 1993) |
| "Dapsone has been utilized for the prevention of Pneumocystis jirovecii pneumonia in immunosuppressed patients including pediatric kidney transplant recipients, in whom trimethoprim-sulfamethoxazole (TMP-SMX) is contraindicated." | 5.62 | Dapsone-induced methemoglobinemia in pediatrics post-renal transplant. ( Hindka, A; Huynh, D; Verghese, PS, 2021) |
| " Though these drugs are generally well tolerated, they can result in potentially severe adverse effects." | 5.56 | Murphy's law in force: sequential adverse events encountered during the treatment of Pneumocystis pneumonia (cotrimoxazole-induced acute peripheral neuropathy and primaquine-induced methemoglobinemia). ( Agarwal, R; Dhooria, S; Muthu, V; Prasad, KT; Saxena, P; Sehgal, IS, 2020) |
| "To the best of our knowledge, acute generalised exanthematous pustulosis has not been reported as a reaction to dapsone in the setting of HIV." | 5.39 | Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone. ( Laws, P; Marsland, A; McQuillan, O; Vas, A, 2013) |
| "We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone." | 5.38 | Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy. ( Blanton, LS; East, J, 2012) |
| "Dapsone therapy was initiated on day +28 at a dose of 100 mg/day for PCP prophylaxis secondary to the patient's history of a sulfonamide allergy." | 5.33 | The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation. ( Abidi, MH; Ibrahim, RB; Kozlowski, JR; Peres, E, 2006) |
| "We assessed the incidence and determinants of bacteremia, pneumonia, and sinusitis/otitis in HIV-positive people receiving cotrimoxazole (CTX) or dapsone-pyrimethamine (DP) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) within a randomized clinical trial." | 5.09 | Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial. ( Ammassari, A; Antinori, A; Cingolani, A; De Luca, A; Grillo, R; Murri, R; Pallavicini, F; Pezzotti, P, 2001) |
| "To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/or CD4 lymphocyte counts of < 200/microL were randomized to receive dapsone/pyrimethamine (200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks)." | 5.08 | Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. ( Heald, A; Hirschel, B; Iten, A; Lazzarin, A; Oertle, D; Opravil, M; Pechère, M; Praz, G; Rüttimann, S; von Overbeck, J, 1995) |
| "To examine the interaction between dapsone and trimethoprim in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.06 | Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. ( Benowitz, NL; Jacob, P; Lee, BL; Medina, I; Mills, J; Wofsy, CB, 1989) |
| "From 1936 until 1996, the drug dapsone treated a diverse array of diseases, including tuberculosis, leprosy, malaria, and AIDS-related pneumonia." | 4.87 | A short history of dapsone, or an alternative model of drug development. ( Barr, J, 2011) |
| "To report a case of methemoglobinemia in a patient receiving dapsone for prophylaxis of Pneumocystis carinii pneumonia (PCP)." | 4.80 | Dapsone-induced methemoglobinemia. ( McCarthy, MW; Ward, KE, 1998) |
| " For dapsone, among 100 patients given 100 mg daily instead of twice a week for 1 year (primary prophylaxis), seven fewer patients would develop P carinii pneumonia, but 17 more would have significant toxic reactions." | 4.79 | A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. ( Cappelleri, JC; Ioannidis, JP; Lau, J; Sacks, HS; Skolnik, PR, 1996) |
| "In a meta-analysis, we examined the efficacy of aerosolized pentamidine, trimethoprim-sulfamethoxazole, and dapsone or dapsone/pyrimethamine for the prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in patients with HIV infection." | 4.79 | Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. ( Bucher, HC; Griffith, L; Guyatt, GH; Opravil, M, 1997) |
| "Diaphenylsulfone (DDS: Dapsone) is used for Pneumocystis pneumonia (PCP) prophylaxis, and methemoglobinemia has rarely been reported as a side effect of DDS." | 3.81 | Identifying the Cause of the "Saturation Gap": Two Cases of Dapsone-induced Methemoglobinemia. ( Arita, M; Furuta, K; Hashimoto, T; Ikeda, S; Ikeo, S; Ishida, T; Ito, A; Nishiyama, A; Tachibana, H; Takaiwa, T; Tanaka, M; Tokioka, F; Yokoyama, T; Yoshioka, H, 2015) |
| "From 1936 until 1996, the drug dapsone treated a diverse array of diseases, including tuberculosis, leprosy, malaria, and AIDS-related pneumonia." | 3.77 | A short history of dapsone, or an alternative model of drug development. ( Barr, J, 2011) |
| "Among 167 pediatric patients treated for hematologic malignancies or aplastic anemia who received dapsone for PCP prophylaxis, demographic and dapsone treatment data were retrospectively collected." | 3.77 | Dapsone-induced methemoglobinemia: a dose-related occurrence? ( Esbenshade, AJ; Friedman, DL; Ho, RH; Shintani, A; Smith, LA; Zhao, Z, 2011) |
| "We studied 15 children with acute lymphoblastic leukemia (ALL) receiving dapsone for PCP prophylaxis to determine the frequency of methemoglobinemia, and correlate its occurrence with cytochrome b5 reductase (Cb5R) enzyme levels." | 3.73 | Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. ( Athale, UH; Barr, RD; Hoyer, JD; MacDonald, P; Williams, S, 2005) |
| "This report describes a case of methemoglobinemia in association with dapsone therapy." | 3.73 | Methemoglobinemia associated with dapsone therapy in a child with pneumonia and chronic immune thrombocytopenic purpura. ( Roberts, WD; Schiff, DE; Sue, YJ, 2006) |
| "Dapsone, used for prevention of Pneumocystis jirovecii infections, has been reported to cause hemolytic anemia and methemoglobinemia; its tolerability in solid organ transplant recipients is not well described." | 3.73 | Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. ( Barton, TD; Bloom, RD; Blumberg, EA; Chojnowski, D; Doyle, AM; Goral, S; Korenda, K; Lee, I, 2005) |
| "A 34-year-old woman with HIV infection and no other opportunistic infections presented a classic sulfone syndrome, manifested by fever, rash, hemolytic anemia, and fulminant hepatitis due to dapsone hypersensitive reaction, with a fatal outcome." | 3.69 | Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient. ( Baffoe-Bonnie, H; Chalasani, P; Jurado, RL, 1994) |
| "The efficacy, toxicity and cost of orally administered dapsone (50-100 mg/day) for prophylaxis of Pneumocystis carinii pneumonia (PCP) were evaluated in 30 patients with AIDS or AIDS-related complex (ARC)." | 3.68 | Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. ( Deresinski, SC; Greene, SI; Kemper, CA; Kessinger, JM; Lang, OS; Stevens, DA; Tucker, RM, 1990) |
| "All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight X d)." | 3.67 | Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, W; Leoung, GS; Mills, J; Wofsy, C, 1986) |
| "All patients with the acquired immunodeficiency syndrome treated for their first episode of Pneumocystis carinii pneumonia at San Francisco General Hospital between 1 April 1985 and 15 July 1985 were evaluated for their response to treatment with dapsone (100 mg/day) by mouth for 21 days." | 3.67 | Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, WT; Leoung, G; Medina, I; Mills, J; Wofsy, C, 1988) |
| "A 44-year-old man with acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia (PCP) who suffered adverse effects from treatment with trimethoprim-sulfamethoxazole (TMP-SMX) and was then treated with pentamidine isethionate is described, and approved and investigational drugs used in the management of PCP in the AIDS patient are discussed." | 3.67 | Treatment of Pneumocystis carinii pneumonia in patients with AIDS. ( Hauptman, SP; Wordell, CJ, 1988) |
| "Previous studies of dapsone pharmacokinetics in children have been too small to allow assessment of the relationships between dapsone pharmacokinetic parameters and patient characteristics or markers of efficacy and toxicity." | 2.70 | Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. ( Bonagura, VR; Capparelli, E; Cooper, E; Jacobus, D; Lindsey, J; McIntosh, K; Mirochnick, M; Mofenson, L; Nachman, S; Spector, SA; Sullivan, JL; Xu, J; Yogev, R, 2001) |
| "The P." | 2.69 | Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. ( Armstrong, W; Burman, W; Crane, L; Hossler, PA; Katz, J; Kazanjian, P; Lee, CH; Meshnick, SR; Richardson, J, 2000) |
| " For the entire population, the median half-life was 22." | 2.69 | Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. ( Bonagura, VR; Cooper, E; Cunningham, CK; Dankner, W; Frenkel, LM; Jacobus, D; Johnson, D; Lindsey, J; McIntosh, K; McNamara, J; Mirochnick, M; Mofenson, L; Nachman, S; Rathore, MH; Sullivan, JL; Wara, DW; Xu, J, 1999) |
| " Serial blood samples were obtained over 24 hours after dosing and analyzed for trimetrexate, dapsone, and monoacetyldapsone, and pharmacokinetic parameters were determined." | 2.69 | Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ( Chatterjee, DJ; Dubé, MP; Koda, RT; Li, WY; Sattler, FR; Stansell, JD, 1999) |
| "Dapsone is an alternative drug for Pneumocystis carinii pneumonia (PCP) prophylaxis in individuals intolerant to trimethoprim-sulfamethoxazole (T/S)." | 2.69 | Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group. ( Bonagura, V; Cooper, E; Jacobus, D; Kovacs, A; Lindsey, J; McIntosh, K; McNamara, J; Mirochnick, M; Mofenson, L; Nachman, S; Sacks, H; Sleasman, J; Spector, SA; Sullivan, JL; Xu, J; Yogev, R, 1999) |
| "The test is applied on AIDS prophylaxis and paediatric trials." | 2.69 | Combining mortality and longitudinal measures in clinical trials. ( Finkelstein, DM; Schoenfeld, DA, 1999) |
| "Rifampin was found to increase the values of clearance/bioavailability (CL/F) and volume of distribution/ bioavailability (V/F) by approximately 70%." | 2.68 | Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. ( Bassetti, D; Casazza, R; Cruciani, M; Gatti, G; Hossein, J; Karlsson, M; Merighi, M; Travaini, S, 1996) |
| " However, the suggested dosage regimen is based upon clinical experience with children with leprosy and dermatitis herpetiformis rather than pharmacokinetic and pharmacodynamic data obtained from the target patient population." | 2.68 | Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. ( Bassetti, D; Casazza, R; Cruciani, M; Gatti, G; Loy, A; Miletich, F, 1995) |
| " Six patients had received oral dapsone for at least 1 month at the dosage regimen of 100 mg twice of three times weekly and four patients had received a single oral 100 mg dose." | 2.68 | Penetration of dapsone into cerebrospinal fluid of patients with AIDS. ( Bassetti, M; Cruciani, M; Gatti, G; Hossein, J; Malena, M, 1997) |
| "Dapsone was discontinued in nine (39%) patients because of adverse reactions." | 2.67 | Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals. ( Horowitz, HW; Jorde, UP; Wormser, GP, 1993) |
| "Standard treatments of HIV-associated Pneumocystis carinii pneumonia (PCP) consist of high dose intravenous or oral cotrimoxazole or intravenous pentamidine." | 2.67 | [Successful treatment of HIV-associated pneumocystis carinii pneumonia with dapsone plus trimethoprim]. ( Laifer, G; Rüttimann, S, 1992) |
| "The development of PCP, transfusion requirements, monthly complete blood cell counts, serious adverse reactions and death were recorded." | 2.67 | Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. ( Hoy, JF; Kent, SJ; Lucas, CR; Pettinger, MB; Slavin, MA; Stewart, K, 1992) |
| "In patients with AIDS, oral therapy with trimethoprim-sulfamethoxazole and with trimethoprim-dapsone are equally effective for mild-to-moderate first episodes of P." | 2.67 | Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. ( Benowitz, N; Hopewell, PC; Lee, B; Leoung, G; Medina, I; Mills, J; Modin, G; Wofsy, CB, 1990) |
| "Dapsone was more effective in the primary prophylaxis of toxoplasmic encephalitis, with six toxoplasmic encephalitis events occurring among those receiving aerosolized pentamidine, compared to none among those taking dapsone (p = 0." | 2.67 | Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. ( Barr, M; Carlo, C; Chanin, E; Gregory, G; Kiely, S; Martin, M; Thorn, M; Thornton, J; Torres, RA, 1993) |
| " The pharmacokinetics of dapsone and pyrimethamine were examined by using a population pharmacokinetic model." | 2.67 | Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia. ( Amantea, MA; Byrne, A; Davey, RT; Falloon, J; Graziani, A; Lavelle, J; Morgan, A; Ogata-Arakaki, D; Ownby, K; Polis, M, 1994) |
| "Dapsone was administered at 50 mg/m2 p." | 2.40 | Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation. ( Chan, KW; Choroszy, M; Gardner, M; Maltezou, HC; Mantzouranis, EC; Petropoulos, D; Rolston, KV, 1997) |
| "Early effective management of Pneumocystis carinii pneumonia improves outcome in patients with this disorder." | 2.40 | Treatment and prophylaxis of Pneumocystis carinii pneumonia. ( Castro, M, 1998) |
| "Although the incidence of Pneumocystis carinii pneumonia (PCP) among adults infected with human immunodeficiency virus (HIV) has declined, no decline in PCP incidence has been observed among HIV-infected children, and PCP remains the most common serious opportunistic infection among both adults and children in the United States." | 2.39 | Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. ( Feinberg, J; Hughes, WT; Navin, TR; Simonds, RJ, 1995) |
| "In addition, patients with AIDS also may exhibit a defect in adrenal function, potentiating the hyperkalemic effect of TMP therapy." | 2.39 | Hyperkalemia and high-dose trimethoprim/sulfamethoxazole. ( Hsu, I; Wordell, CJ, 1995) |
| "Pneumonia is an important cause of morbidity and mortality in the United States." | 2.39 | Prevention of community-acquired and nosocomial pneumonia. ( Santos, MR; Simberkoff, MS, 1996) |
| "The diagnosis of Pneumocystis carinii pneumonia (PCP) rests on the isolation of this micro-organism in patients whose latest blood count, less than 2 months old, shows less than 250 CD4 lymphocytes per cubic mm and who present with signs of impaired lung function." | 2.38 | [Pneumocystis carinii pneumonia in HIV infection. Diagnosis, prognostic factors and curative treatment]. ( Girard, PM; Saimot, AG, 1991) |
| "Although Pneumocystis carinii pneumonia (PCP) can occur in any patient with severe impairment of immunity, there has been a sharp rise in incidence with the spread of human immunodeficiency virus through the USA and Western Europe, where nearly 80% of patients with HIV infection have at least one episode of PCP during their lifetime (Murray et al, 1984)." | 2.38 | Prophylaxis and treatment of Pneumocystis carinii pneumonia. ( Bateman, NT; O'Doherty, MJ, 1991) |
| "Pneumocystis carinii pneumonia is a life-threatening complication of diseases and therapies associated with immunosuppression." | 2.38 | Pneumocystis carinii: a deadly opportunist. ( Tsou, E; Zackrison, LH, 1991) |
| "The continuing growth of the acquired immunodeficiency syndrome (AIDS) epidemic has caused a parallel increase in patients with Pneumocystis carinii pneumonia (PCP)." | 2.38 | Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: pathophysiology, therapy, and prevention. ( Montgomery, AB, 1989) |
| "Dapsone has been utilized for the prevention of Pneumocystis jirovecii pneumonia in immunosuppressed patients including pediatric kidney transplant recipients, in whom trimethoprim-sulfamethoxazole (TMP-SMX) is contraindicated." | 1.62 | Dapsone-induced methemoglobinemia in pediatrics post-renal transplant. ( Hindka, A; Huynh, D; Verghese, PS, 2021) |
| " Though these drugs are generally well tolerated, they can result in potentially severe adverse effects." | 1.56 | Murphy's law in force: sequential adverse events encountered during the treatment of Pneumocystis pneumonia (cotrimoxazole-induced acute peripheral neuropathy and primaquine-induced methemoglobinemia). ( Agarwal, R; Dhooria, S; Muthu, V; Prasad, KT; Saxena, P; Sehgal, IS, 2020) |
| "International guidelines for Pneumocystis jirovecii pneumonia (PJP) prevention recommend prophylaxis for ≥6 months following allogeneic hematopoietic cell transplantation, and longer in patients with graft-versus-host disease (GVHD) or on immunosuppressive therapy (IST)." | 1.56 | High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era. ( Chaudhry, A; Dabas, R; Daly, A; Dharmani-Khan, P; Dowhan, M; Duggan, P; Evernden, C; Gregson, D; Jamani, K; Jimenez-Zepeda, V; Johnson, A; Jupp, J; Kalra, A; Khan, F; Storek, J; Tay, J, 2020) |
| "Dapsone may be used for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in hematology patients receiving immunosuppressive therapy or after hematopoietic stem cell transplant (HSCT) in the setting of trimethoprim-sulfamethoxazole (TMP-SMX) adverse drug reaction (ADR) history." | 1.48 | Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients. ( Pisasale, D; Trubiano, JA; Urbancic, KF; Wight, J, 2018) |
| " In 2005, the University of Kentucky (UK) Transplant Center implemented a novel dosing regimen of weekly dapsone as an alternative for patients with contraindications or intolerability to trimethoprim-sulfamethoxazole (TMP-SMZ), which remains the drug of choice." | 1.42 | Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation. ( Au, T; Clifford, TM; Evans, RA; Fugit, AM; Tang, S, 2015) |
| "To the best of our knowledge, acute generalised exanthematous pustulosis has not been reported as a reaction to dapsone in the setting of HIV." | 1.39 | Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone. ( Laws, P; Marsland, A; McQuillan, O; Vas, A, 2013) |
| "We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone." | 1.38 | Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy. ( Blanton, LS; East, J, 2012) |
| "Methemoglobinemia is a rare pathology that results from the oxidation of iron in the hemoglobin molecule." | 1.38 | Two cases of acquired methemoglobinemia. ( Bergmans, D; Hall, A; Schnabel, R; Stessel, B, 2012) |
| "Dapsone has several adverse effects in its profile that make it a potentially dangerous second-line agent." | 1.33 | Adverse reactions associated with dapsone therapy in HIV-positive patients: a case presentation and review. ( Miller, JA; Reust, R; Stephens, JR; Stroup, JS, 2006) |
| "Dapsone therapy was initiated on day +28 at a dose of 100 mg/day for PCP prophylaxis secondary to the patient's history of a sulfonamide allergy." | 1.33 | The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation. ( Abidi, MH; Ibrahim, RB; Kozlowski, JR; Peres, E, 2006) |
| "PCR sensitivity and specificity were 100 and 86." | 1.32 | Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects. ( Carrera, P; Lazzarin, A; Scarpellini, P; Zingale, A, 2003) |
| "We report a patient with AIDS who developed a dapsone-induced hypersensitivity pneumonitis mimicking Pneumocystis carinii (PCP) pneumonia." | 1.32 | Dapsone-induced hypersensitivity pneumonitis mimicking Pneumocystis carinii pneumonia in a patient with AIDS. ( Brown, KV; Hoteit, MA; King, MD; Ray, SM; Tobin-D'Angelo, MJ, 2004) |
| " Dapsone prophylaxis at this dosage is associated with significantly higher rates of PCP than is TMP-SMZ after allogeneic marrow transplantation." | 1.30 | High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. ( Boeckh, M; Crawford, SW; Flowers, ME; Gooley, TA; Souza, JP, 1999) |
| " Overall results from these studies indicate patients who are eligible for PCP prophylaxis should be advised to take double-strength trimethoprim/sulfamethoxazole (TMP/SMX) on a daily basis, a dosage found more effective than thrice-weekly." | 1.30 | Optimizing PCP therapy. ( Cadman, J; Torres, G, 1997) |
| "Failures of prophylaxis against Pneumocystis carinii pneumonia (PCP) in AIDS patients do occur, but no evidence for drug resistance has yet been presented." | 1.30 | Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. ( Bartlett, MS; Cannon, M; Hossler, PA; Kazanjian, P; Lane, BR; Locke, AB; Meshnick, SR; Smith, JW, 1998) |
| " Dosing or frequency of TMP-SMX did not seem to influence risk of chemoprophylaxis failure." | 1.30 | Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators. ( Holmberg, SD; Moorman, AC; Palella, FJ; Von Bargen, JC, 1998) |
| "Dapsone is a cheap and effective prophylactic agent against P carinii in patients who cannot tolerate trimethoprim-sulfamethoxazole." | 1.30 | Bilateral upper-lobe cavitary Pneumocystis carinii pneumonia in a patient on dapsone prophylaxis. ( Anandarao, N; Dama, S; Jawahar, DA; Miarrostami, R; Sadagdhar, H, 1999) |
| "Six cases of pneumocystis carinii pneumonia were retrospectively analyzed." | 1.30 | [A clinical study of six cases of Pneumocystis carinii pneumonia]. ( Lin, X; Wu, S, 1998) |
| "Dapsone was taken for an average of 7." | 1.29 | Efficacy and safety of dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children. ( Noel, GJ; Stavola, JJ, 1993) |
| " Ro 11-8958, TMP, and diaveridine used at a dosage of 20 mg/kg/day with SMX were only slightly more effective than SMX used alone." | 1.29 | Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. ( Foy, J; Steele, P; Walzer, PD; White, M, 1993) |
| "Pneumocystis carinii pneumonia has been the most common life-threatening opportunistic infection in patients with acquired immunodeficiency syndrome." | 1.29 | Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia. ( Glatt, AE, 1994) |
| "One patient had a recurrence of PCP at 4 mo, after a negative 1-mo BAL." | 1.29 | Persistence of Pneumocystis carinii in patients with AIDS receiving chemoprophylaxis. ( Antonson, S; Epstein, LJ; Meyer, RD; Mohsenifar, Z; Strigle, SM, 1994) |
| "Drug therapies for patients with human immunodeficiency virus (HIV) infection are associated with adverse events that can potentially limit their effectiveness." | 1.29 | Adverse events from drug therapy for human immunodeficiency virus disease. ( Chaisson, RE; Fortgang, I; Keruly, J; Moore, RD, 1996) |
| "The overall incidence of adverse events (AE) in our study cohort was 39%." | 1.29 | Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. ( Beumont, MG; Graziani, A; MacGregor, RR; Ubel, PA, 1996) |
| "carinii prophylaxis before the onset of AIDS: Mycobacterium avium complex disease, which developed in 33." | 1.29 | Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. ( Anderson, R; Bacellar, H; Detels, R; Hoover, DR; Kaslow, RA; Phair, J; Saah, AJ, 1993) |
| "The prophylactic efficacies of atovaquone (ATQ) alone and in combination with azithromycin, clarithromycin, rifabutin, proguanil, PS-15, trimethoprim, co-trimoxazole, or dapsone were investigated in a SCID mouse model of Pneumocystis carinii pneumonia (PCP)." | 1.29 | Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. ( Comley, JC; Sterling, AM, 1995) |
| "Occurrence or recurrence of PCP." | 1.29 | Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. ( Hoover, DR; Kingsley, LA; Peng, Y; Phair, JP; Saah, AJ; Schrager, LK; Visscher, B, 1995) |
| "Dapsone has been proposed as a prophylactic agent for both Pneumocystis carinii pneumonia (PCP) and reactivation cerebral toxoplasmosis." | 1.29 | Dapsone penetrates cerebrospinal fluid during Pneumocystis carinii pneumonia prophylaxis. ( Mirochnick, M; Rich, JD, 1996) |
| "Extrapulmonary pneumocystosis is a feature of severe immunosuppression which earlier reports have suggested is limited to patients receiving either no prophylaxis or aerosolised pentamidine." | 1.29 | Systemic Pneumocystis carinii pneumonia prophylaxis with dapsone and pyrimethamine fails to protect against extrapulmonary pneumocystosis. ( Carlin, EM; Coker, RJ; Goldin, RD; Harris, JR, 1993) |
| "In 33 consecutive AIDS patients with a first episode of Pneumocystis carinii pneumonia (PCP) we evaluated treatment, outcome, recurrence rate and pyrimethamine as chemoprophylaxis in a 1-year follow-up." | 1.28 | Pneumocystis carinii pneumonia in Stockholm, Sweden: treatment, outcome, one-year-follow-up and pyrimethamine prophylaxis. ( Bergdahl, S; Julander, I; Lidman, C; Lundbergh, P; Ortqvist, A, 1989) |
| "The prevention of the occurrence and recurrence of PCP is a cornerstone in the treatment of patients infected with the human immunodeficiency virus." | 1.28 | A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. ( Beall, GN; Beck, K; Cox, PH; Martin, MA; Styer, CM, 1992) |
| " carinii in vitro, a clinical trial of reduced dosage of dapsone given prophylactically to human beings is suggested." | 1.28 | Dapsone in low doses prevents Pneumocystis carinii pneumonia in the rat model. ( González-Ruiz, A; Haworth, SJ; O'Neil, AB; Warhurst, DC, 1991) |
| "Suramin and dapsone were weakly active." | 1.27 | Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia. ( Clarkson, AB; Rosenberg, C; Williams, DE, 1988) |
| "The purpose of this study was to identify new drugs for the prevention and treatment of Pneumocystis carinii pneumonitis (PCP) induced in rats by continuous daily dosage with dexamethasone." | 1.27 | Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. ( Hughes, WT; Smith, BL, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (11.63) | 18.7374 |
| 1990's | 133 (61.86) | 18.2507 |
| 2000's | 27 (12.56) | 29.6817 |
| 2010's | 21 (9.77) | 24.3611 |
| 2020's | 9 (4.19) | 2.80 |
| Authors | Studies |
|---|---|
| Queener, SF | 1 |
| Vandermeersch, D | 1 |
| Sansen, PY | 1 |
| Pothen, L | 1 |
| Evernden, C | 1 |
| Dowhan, M | 1 |
| Dabas, R | 1 |
| Chaudhry, A | 1 |
| Kalra, A | 1 |
| Dharmani-Khan, P | 1 |
| Gregson, D | 1 |
| Johnson, A | 1 |
| Jupp, J | 1 |
| Jimenez-Zepeda, V | 1 |
| Jamani, K | 1 |
| Duggan, P | 1 |
| Tay, J | 1 |
| Khan, F | 1 |
| Daly, A | 1 |
| Storek, J | 1 |
| Sahu, KK | 1 |
| Lal, A | 1 |
| Mishra, AK | 1 |
| George, SV | 1 |
| Saxena, P | 1 |
| Muthu, V | 1 |
| Dhooria, S | 1 |
| Sehgal, IS | 1 |
| Prasad, KT | 1 |
| Agarwal, R | 1 |
| Corallo, CE | 1 |
| Coutsouvelis, J | 1 |
| Morgan, S | 1 |
| Morrissey, O | 1 |
| Avery, S | 1 |
| Hindka, A | 1 |
| Huynh, D | 1 |
| Verghese, PS | 1 |
| Urbancic, KF | 1 |
| Pisasale, D | 1 |
| Wight, J | 1 |
| Trubiano, JA | 1 |
| Siscos, SM | 2 |
| Neill, BC | 2 |
| Tarantino, IS | 2 |
| Aires, DJ | 2 |
| Rajpara, A | 2 |
| Kneiber, D | 1 |
| Kowalski, EH | 1 |
| Amber, KT | 1 |
| Torabi, J | 1 |
| Campbell, A | 1 |
| Nair, G | 1 |
| Patel, GL | 1 |
| Miura, Y | 1 |
| Graham, JA | 1 |
| Vas, A | 1 |
| Laws, P | 1 |
| Marsland, A | 1 |
| McQuillan, O | 1 |
| Mitsides, N | 1 |
| Green, D | 1 |
| Middleton, R | 1 |
| New, D | 1 |
| Lamerton, E | 1 |
| Allen, J | 1 |
| Redshaw, J | 1 |
| Chadwick, PR | 1 |
| Subudhi, CP | 1 |
| Wood, G | 1 |
| Barr, J | 2 |
| Malasingam, R | 1 |
| Ranganathan, D | 1 |
| Jeyaseelan, L | 1 |
| Ramanathan, K | 1 |
| Jacks, M | 1 |
| Owens, J | 1 |
| John, GT | 1 |
| Furuta, K | 1 |
| Ikeo, S | 1 |
| Takaiwa, T | 1 |
| Ikeda, S | 1 |
| Nishiyama, A | 1 |
| Yokoyama, T | 1 |
| Ito, A | 1 |
| Tokioka, F | 1 |
| Tanaka, M | 1 |
| Yoshioka, H | 1 |
| Tachibana, H | 1 |
| Arita, M | 1 |
| Hashimoto, T | 1 |
| Ishida, T | 1 |
| Evans, RA | 1 |
| Clifford, TM | 1 |
| Tang, S | 1 |
| Au, T | 1 |
| Fugit, AM | 1 |
| Rizk, N | 1 |
| Kamiya-Matsuoka, C | 1 |
| Tremont-Lukats, IW | 1 |
| Diri, R | 1 |
| Anwer, F | 1 |
| Yeager, A | 1 |
| Krishnadasan, R | 1 |
| McBride, A | 1 |
| Ponce, CA | 1 |
| Chabé, M | 1 |
| George, C | 1 |
| Cárdenas, A | 1 |
| Durán, L | 1 |
| Guerrero, J | 1 |
| Bustamante, R | 1 |
| Matos, O | 1 |
| Huang, L | 4 |
| Miller, RF | 1 |
| Vargas, SL | 1 |
| Nazir, HF | 1 |
| Elshinawy, M | 1 |
| AlRawas, A | 1 |
| Khater, D | 1 |
| Zadjaly, S | 1 |
| Wali, Y | 1 |
| White, PL | 1 |
| Backx, M | 1 |
| Barnes, RA | 1 |
| Wozel, VE | 1 |
| Subramaniam, A | 1 |
| Corallo, C | 1 |
| Nagappan, R | 1 |
| Esbenshade, AJ | 1 |
| Ho, RH | 1 |
| Shintani, A | 1 |
| Zhao, Z | 1 |
| Smith, LA | 1 |
| Friedman, DL | 1 |
| East, J | 1 |
| Blanton, LS | 1 |
| Lim, PL | 1 |
| Zhou, J | 1 |
| Ditangco, RA | 1 |
| Law, MG | 1 |
| Sirisanthana, T | 1 |
| Kumarasamy, N | 2 |
| Chen, YM | 1 |
| Phanuphak, P | 1 |
| Lee, CK | 1 |
| Saphonn, V | 1 |
| Oka, S | 1 |
| Zhang, F | 1 |
| Choi, JY | 1 |
| Pujari, S | 1 |
| Kamarulzaman, A | 1 |
| Li, PC | 1 |
| Merati, TP | 1 |
| Yunihastuti, E | 1 |
| Messerschmidt, L | 1 |
| Sungkanuparph, S | 1 |
| Hall, A | 1 |
| Stessel, B | 1 |
| Bergmans, D | 1 |
| Schnabel, R | 1 |
| Gambra, MP | 1 |
| Bidart, T | 1 |
| Zingale, A | 1 |
| Carrera, P | 1 |
| Lazzarin, A | 3 |
| Scarpellini, P | 1 |
| James, CW | 1 |
| McNelis, KC | 1 |
| Szabo, S | 1 |
| Clark-Price, SC | 1 |
| Cox, JH | 1 |
| Bartoe, JT | 1 |
| Davis, EG | 1 |
| Tobin-D'Angelo, MJ | 1 |
| Hoteit, MA | 1 |
| Brown, KV | 1 |
| Ray, SM | 1 |
| King, MD | 1 |
| Kazanjian, PH | 1 |
| Fisk, D | 1 |
| Armstrong, W | 2 |
| Shulin, Q | 1 |
| Liwei, H | 1 |
| Ke, Z | 1 |
| Meshnick, S | 1 |
| Williams, S | 1 |
| MacDonald, P | 1 |
| Hoyer, JD | 1 |
| Barr, RD | 1 |
| Athale, UH | 1 |
| Crothers, K | 1 |
| Atzori, C | 1 |
| Benfield, T | 1 |
| Miller, R | 1 |
| Rabodonirina, M | 1 |
| Helweg-Larsen, J | 1 |
| Bellamy, R | 3 |
| Lee, I | 1 |
| Barton, TD | 1 |
| Goral, S | 1 |
| Doyle, AM | 1 |
| Bloom, RD | 1 |
| Chojnowski, D | 1 |
| Korenda, K | 1 |
| Blumberg, EA | 1 |
| Vallabhaneni, S | 1 |
| Cecelia, AJ | 1 |
| Mayer, KH | 1 |
| Solomon, S | 1 |
| Carpenter, CC | 1 |
| Flanigan, TP | 1 |
| Stroup, JS | 1 |
| Stephens, JR | 1 |
| Reust, R | 1 |
| Miller, JA | 1 |
| Abidi, MH | 1 |
| Kozlowski, JR | 1 |
| Ibrahim, RB | 1 |
| Peres, E | 1 |
| Schiff, DE | 1 |
| Roberts, WD | 1 |
| Sue, YJ | 1 |
| Mitchell, B | 1 |
| Hughes, WT | 8 |
| Smith, BL | 2 |
| Gatti, G | 7 |
| Loy, A | 2 |
| Casazza, R | 2 |
| Miletich, F | 2 |
| Cruciani, M | 6 |
| Bassetti, D | 6 |
| Hsu, I | 1 |
| Wordell, CJ | 2 |
| Hoernle, EH | 1 |
| Reid, TE | 1 |
| Salmon-Ceron, D | 1 |
| Fontbonne, A | 1 |
| Saba, J | 1 |
| May, T | 1 |
| Raffi, F | 1 |
| Chidiac, C | 1 |
| Patey, O | 1 |
| Aboulker, JP | 1 |
| Schwartz, D | 1 |
| Vildé, JL | 1 |
| Rydzewski, B | 1 |
| Davis, R | 1 |
| Saah, AJ | 2 |
| Hoover, DR | 2 |
| Peng, Y | 1 |
| Phair, JP | 1 |
| Visscher, B | 1 |
| Kingsley, LA | 1 |
| Schrager, LK | 1 |
| Podzamczer, D | 3 |
| Salazar, A | 1 |
| Jiménez, J | 2 |
| Consiglio, E | 1 |
| Santín, M | 3 |
| Casanova, A | 2 |
| Rufí, G | 1 |
| Gudiol, F | 2 |
| Opravil, M | 7 |
| Pechère, M | 2 |
| Heald, A | 2 |
| Rüttimann, S | 3 |
| Iten, A | 2 |
| Furrer, H | 1 |
| Oertle, D | 2 |
| Praz, G | 2 |
| Vuitton, DA | 1 |
| Hirschel, B | 2 |
| von Overbeck, J | 1 |
| Comley, JC | 1 |
| Sterling, AM | 1 |
| Nachman, SA | 1 |
| Mueller, BU | 1 |
| Mirochnick, M | 6 |
| Pizzo, PA | 1 |
| Clumeck, N | 2 |
| Bozzette, SA | 1 |
| Finkelstein, DM | 3 |
| Spector, SA | 3 |
| Frame, P | 2 |
| Powderly, WG | 1 |
| He, W | 1 |
| Phillips, L | 1 |
| Craven, D | 1 |
| van der Horst, C | 2 |
| Feinberg, J | 4 |
| Bacellar, H | 1 |
| Phair, J | 1 |
| Detels, R | 1 |
| Anderson, R | 1 |
| Kaslow, RA | 1 |
| Epstein, LJ | 1 |
| Meyer, RD | 1 |
| Antonson, S | 1 |
| Strigle, SM | 1 |
| Mohsenifar, Z | 1 |
| Chalasani, P | 1 |
| Baffoe-Bonnie, H | 1 |
| Jurado, RL | 1 |
| Falloon, J | 1 |
| Lavelle, J | 1 |
| Ogata-Arakaki, D | 1 |
| Byrne, A | 1 |
| Graziani, A | 2 |
| Morgan, A | 1 |
| Amantea, MA | 1 |
| Ownby, K | 1 |
| Polis, M | 1 |
| Davey, RT | 1 |
| Pastor, C | 1 |
| Lumbreras, C | 1 |
| Lizasoain, M | 1 |
| Torres, RA | 1 |
| Barr, M | 1 |
| Thorn, M | 1 |
| Gregory, G | 1 |
| Kiely, S | 1 |
| Chanin, E | 1 |
| Carlo, C | 1 |
| Martin, M | 1 |
| Thornton, J | 1 |
| Pertel, P | 1 |
| Hirschtick, R | 1 |
| Tocchetti, A | 1 |
| Tambini, R | 1 |
| Allegro, A | 1 |
| Longoni, E | 1 |
| Rinaldi, E | 1 |
| Joos, B | 1 |
| Lüthy, R | 4 |
| Huengsberg, M | 1 |
| Castelino, S | 1 |
| Sherrard, J | 1 |
| O'Farrell, N | 1 |
| Bingham, J | 1 |
| Glatt, AE | 1 |
| Barnett, ED | 1 |
| Pelton, SI | 1 |
| Cooper, ER | 1 |
| Concia, E | 1 |
| Fioredda, F | 2 |
| Walzer, PD | 2 |
| Foy, J | 1 |
| Steele, P | 1 |
| White, M | 1 |
| Lang, W | 1 |
| Osmond, D | 1 |
| Page-Bodkin, K | 1 |
| Moss, A | 1 |
| Winkelstein, W | 1 |
| Stavola, JJ | 1 |
| Noel, GJ | 1 |
| Weintrub, PS | 1 |
| Wara, DW | 2 |
| Duliege, AM | 1 |
| Mallolas, J | 3 |
| Zamora, L | 3 |
| Gatell, JM | 3 |
| Miró, JM | 2 |
| Vernet, E | 1 |
| Valls, ME | 1 |
| Soriano, E | 2 |
| SanMiguel, JG | 1 |
| Khaliq, Y | 1 |
| Lamp, KC | 1 |
| Martos, A | 1 |
| Ferrer, I | 1 |
| Jorde, UP | 3 |
| Horowitz, HW | 4 |
| Wormser, GP | 4 |
| Sabin, CA | 1 |
| Phillips, AN | 1 |
| Girard, PM | 3 |
| Landman, R | 1 |
| Gaudebout, C | 2 |
| Olivares, R | 1 |
| Saimot, AG | 2 |
| Jelazko, P | 1 |
| Certain, A | 1 |
| Boué, F | 1 |
| Bouvet, E | 1 |
| Bolao, F | 1 |
| Gudiol, GR | 1 |
| Carlin, EM | 1 |
| Coker, RJ | 2 |
| Goldin, RD | 1 |
| Harris, JR | 2 |
| Teuscher, AU | 1 |
| Theiler, R | 1 |
| Speich, R | 1 |
| Kuster, H | 1 |
| Siegenthaler, W | 1 |
| Russi, EW | 1 |
| Keusch, G | 1 |
| Ioannidis, JP | 2 |
| Cappelleri, JC | 1 |
| Skolnik, PR | 1 |
| Lau, J | 2 |
| Sacks, HS | 1 |
| Simonds, RJ | 1 |
| Navin, TR | 2 |
| Goebel, FD | 1 |
| Bogner, JR | 1 |
| Korraa, H | 1 |
| Saadeh, C | 1 |
| Antinori, A | 5 |
| Murri, R | 5 |
| Ammassari, A | 3 |
| De Luca, A | 4 |
| Linzalone, A | 1 |
| Cingolani, A | 2 |
| Damiano, F | 1 |
| Maiuro, G | 1 |
| Vecchiet, J | 1 |
| Scoppettuolo, G | 1 |
| Safrin, S | 2 |
| Simpson, G | 1 |
| Wu, A | 1 |
| Cheung, T | 1 |
| Soeiro, R | 1 |
| Hojczyk, P | 1 |
| Black, JR | 1 |
| Weinberg, GA | 1 |
| Beumont, MG | 1 |
| Ubel, PA | 1 |
| MacGregor, RR | 1 |
| Tamburrini, E | 2 |
| Mencarini, P | 1 |
| Visconti, E | 1 |
| Zolfo, M | 1 |
| Siracusano, A | 1 |
| Ortona, E | 1 |
| Moore, RD | 1 |
| Fortgang, I | 1 |
| Keruly, J | 1 |
| Chaisson, RE | 1 |
| Sin, DD | 1 |
| Shafran, SD | 1 |
| Garavelli, PL | 1 |
| Lorusso, C | 2 |
| Barber, BA | 1 |
| Pegram, PS | 1 |
| High, KP | 1 |
| Merighi, M | 1 |
| Hossein, J | 2 |
| Travaini, S | 1 |
| Karlsson, M | 1 |
| Mengoli, C | 1 |
| Cazzadori, A | 1 |
| Lazzarini, L | 1 |
| Graziani, MS | 1 |
| Malena, M | 2 |
| Rich, JD | 1 |
| Rossi, G | 1 |
| Deresinski, SC | 2 |
| Easterbrook, PJ | 1 |
| Bucher, HC | 1 |
| Griffith, L | 1 |
| Guyatt, GH | 1 |
| Bassetti, M | 1 |
| Plotkin, JS | 1 |
| Buell, JF | 1 |
| Njoku, MJ | 1 |
| Wilson, S | 1 |
| Kuo, PC | 1 |
| Bartlett, ST | 1 |
| Howell, C | 1 |
| Johnson, LB | 1 |
| Simberkoff, MS | 1 |
| Santos, MR | 1 |
| Maltezou, HC | 1 |
| Petropoulos, D | 1 |
| Choroszy, M | 1 |
| Gardner, M | 1 |
| Mantzouranis, EC | 1 |
| Rolston, KV | 1 |
| Chan, KW | 1 |
| Fishman, JA | 2 |
| Ward, KE | 1 |
| McCarthy, MW | 1 |
| Kazanjian, P | 2 |
| Locke, AB | 1 |
| Hossler, PA | 2 |
| Lane, BR | 1 |
| Bartlett, MS | 1 |
| Smith, JW | 1 |
| Cannon, M | 1 |
| Meshnick, SR | 3 |
| Moorman, AC | 1 |
| Von Bargen, JC | 1 |
| Palella, FJ | 1 |
| Holmberg, SD | 1 |
| Sackoff, J | 1 |
| McFarland, J | 1 |
| Su, S | 1 |
| Bryan, E | 1 |
| El-Sadr, WM | 1 |
| Murphy, RL | 1 |
| Yurik, TM | 1 |
| Luskin-Hawk, R | 1 |
| Cheung, TW | 1 |
| Balfour, HH | 1 |
| Eng, R | 1 |
| Hooton, TM | 1 |
| Kerkering, TM | 1 |
| Schutz, M | 1 |
| Hafner, R | 2 |
| Payen, MC | 1 |
| De Wit, S | 1 |
| Sommereijns, B | 1 |
| Castro, M | 1 |
| Cook, DE | 1 |
| Kossey, JL | 1 |
| Jawahar, DA | 1 |
| Dama, S | 1 |
| Miarrostami, R | 1 |
| Sadagdhar, H | 1 |
| Anandarao, N | 1 |
| Koda, RT | 1 |
| Dubé, MP | 1 |
| Li, WY | 1 |
| Chatterjee, DJ | 1 |
| Stansell, JD | 1 |
| Sattler, FR | 3 |
| McIntosh, K | 3 |
| Cooper, E | 3 |
| Xu, J | 3 |
| Lindsey, J | 3 |
| Jacobus, D | 3 |
| Mofenson, L | 3 |
| Yogev, R | 2 |
| Sullivan, JL | 3 |
| Sacks, H | 1 |
| Kovacs, A | 1 |
| Nachman, S | 3 |
| Sleasman, J | 1 |
| Bonagura, V | 1 |
| McNamara, J | 2 |
| Edge, MD | 1 |
| Rimland, D | 2 |
| Schoenfeld, DA | 1 |
| Dankner, W | 1 |
| Frenkel, LM | 1 |
| Johnson, D | 1 |
| Bonagura, VR | 2 |
| Rathore, MH | 1 |
| Cunningham, CK | 1 |
| Ma, L | 1 |
| Borio, L | 1 |
| Masur, H | 2 |
| Kovacs, JA | 2 |
| Souza, JP | 1 |
| Boeckh, M | 1 |
| Gooley, TA | 1 |
| Flowers, ME | 1 |
| Crawford, SW | 1 |
| Seaton, RA | 1 |
| Nathwani, D | 1 |
| Kirk, J | 1 |
| France, AJ | 1 |
| Saillourglénisson, F | 1 |
| Chêne, G | 1 |
| Salmi, LR | 1 |
| Salamon, R | 1 |
| Burman, W | 1 |
| Richardson, J | 1 |
| Lee, CH | 1 |
| Crane, L | 1 |
| Katz, J | 1 |
| Sundar, K | 1 |
| Rosado-Santos, H | 1 |
| Reimer, L | 1 |
| Murray, K | 1 |
| Michael, J | 1 |
| Chaloner, K | 1 |
| Rhame, FS | 1 |
| Dorrell, L | 1 |
| McCallum, AK | 1 |
| Snow, MH | 1 |
| Ong, EL | 1 |
| Blanchet, KD | 1 |
| Cheng, B | 1 |
| Torres, G | 1 |
| Cadman, J | 1 |
| Pezzotti, P | 1 |
| Pallavicini, F | 1 |
| Grillo, R | 1 |
| Capparelli, E | 1 |
| Wu, S | 1 |
| Lin, X | 1 |
| Beard, CB | 2 |
| del Rio, C | 1 |
| Lee, S | 1 |
| Pieniazek, NJ | 1 |
| Carter, JL | 1 |
| Le, T | 1 |
| Hightower, A | 1 |
| Groll, AH | 1 |
| Ritter, J | 1 |
| Müller, FM | 1 |
| Freund, YR | 1 |
| Dousman, L | 1 |
| Riccio, ES | 1 |
| Sato, B | 1 |
| MacGregor, JT | 1 |
| Mohagheghpour, N | 1 |
| Morris, AM | 1 |
| Goldie, SJ | 1 |
| Kaplan, JE | 1 |
| Losina, E | 1 |
| Weinstein, MC | 1 |
| Paltiel, AD | 1 |
| Seage, GR | 1 |
| Craven, DE | 1 |
| Kimmel, AD | 1 |
| Zhang, H | 1 |
| Cohen, CJ | 2 |
| Freedberg, KA | 2 |
| Western, KA | 1 |
| Norman, L | 1 |
| Kaufmann, AG | 1 |
| Ortona, L | 1 |
| Nieman, R | 1 |
| McBride, M | 1 |
| Mitchell, DM | 1 |
| Weber, JN | 1 |
| Laifer, G | 1 |
| Slavin, MA | 1 |
| Hoy, JF | 1 |
| Stewart, K | 1 |
| Pettinger, MB | 1 |
| Lucas, CR | 2 |
| Kent, SJ | 1 |
| Martin, MA | 1 |
| Cox, PH | 1 |
| Beck, K | 1 |
| Styer, CM | 1 |
| Beall, GN | 1 |
| Blum, RN | 1 |
| Miller, LA | 1 |
| Gaggini, LC | 1 |
| Cohn, DL | 1 |
| Mohle-Boetani, J | 1 |
| Akula, SK | 1 |
| Holodniy, M | 1 |
| Katzenstein, D | 1 |
| Garcia, G | 1 |
| Hardy, WD | 2 |
| Tosteson, AN | 1 |
| Cotton, DJ | 1 |
| O'Doherty, MJ | 1 |
| Bateman, NT | 1 |
| Slattery, JT | 1 |
| Unadkat, JD | 1 |
| Gallant, JE | 1 |
| Hoehn-Saric, E | 1 |
| Smith, MD | 1 |
| Zackrison, LH | 1 |
| Tsou, E | 1 |
| Clotet, B | 1 |
| Sirera, G | 1 |
| Romeu, J | 1 |
| Gimeno, JM | 1 |
| Jou, A | 1 |
| Condom, MJ | 1 |
| Tor, J | 1 |
| Foz, M | 1 |
| Metroka, CE | 2 |
| McMechan, MF | 1 |
| Andrada, R | 1 |
| Laubenstein, LJ | 1 |
| Jacobus, DP | 2 |
| Kennedy, W | 1 |
| Dugdale, M | 1 |
| Land, MA | 1 |
| Stein, DS | 1 |
| Weems, JJ | 1 |
| Palte, S | 1 |
| Lancaster, D | 1 |
| Gidan-Kovnar, S | 1 |
| Morrison, RE | 1 |
| Lee, BL | 2 |
| Young, T | 1 |
| Bill, R | 1 |
| Boylan, CT | 1 |
| Mills, J | 5 |
| González-Ruiz, A | 1 |
| Haworth, SJ | 1 |
| O'Neil, AB | 1 |
| Warhurst, DC | 1 |
| Kemper, CA | 1 |
| Tucker, RM | 1 |
| Lang, OS | 1 |
| Kessinger, JM | 1 |
| Greene, SI | 1 |
| Stevens, DA | 1 |
| Crosby, WH | 1 |
| Medina, I | 3 |
| Leoung, G | 2 |
| Hopewell, PC | 3 |
| Lee, B | 1 |
| Modin, G | 1 |
| Benowitz, N | 1 |
| Wofsy, CB | 2 |
| Sandland, AM | 1 |
| Mijch, A | 1 |
| Simpson, JM | 1 |
| Montgomery, AB | 2 |
| Lidman, C | 1 |
| Ortqvist, A | 1 |
| Lundbergh, P | 1 |
| Julander, I | 1 |
| Bergdahl, S | 1 |
| Benowitz, NL | 1 |
| Jacob, P | 1 |
| McKinsey, DS | 1 |
| Durfee, D | 1 |
| Kurtin, PJ | 1 |
| Leoung, GS | 1 |
| Hughes, W | 1 |
| Wofsy, C | 2 |
| Fischl, MA | 1 |
| Hauptman, SP | 1 |
| Clarkson, AB | 1 |
| Williams, DE | 1 |
| Rosenberg, C | 1 |
| Kim, CK | 1 |
| Foy, JM | 1 |
| Linke, MJ | 1 |
| Cushion, MT | 1 |
| Green, ST | 1 |
| Goldberg, DJ | 1 |
| Leach, J | 1 |
| Christie, PR | 1 |
| Kennedy, DH | 1 |
| Reiter, WM | 1 |
| Cimoch, PJ | 1 |
| Edelson, PJ | 1 |
| Friedman-Kien, A | 1 |
| Catterall, JR | 1 |
| Potasman, I | 1 |
| Remington, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection[NCT00000991] | Phase 3 | 600 participants | Interventional | Completed | |||
| A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole in the Treatment of Mild-to-Moderate PCP in Patients With AIDS[NCT00000640] | Phase 3 | 290 participants | Interventional | Completed | |||
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides[NCT00000802] | Phase 3 | 700 participants | Interventional | Completed | |||
| Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection[NCT00000739] | Phase 1 | 96 participants | Interventional | Completed | |||
| Phase 1 Safety Run-in Study and Phase 1b Randomized, Double Blinded, Placebo Controlled Trial[NCT05695521] | Phase 1 | 66 participants (Anticipated) | Interventional | 2023-04-03 | Recruiting | ||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole and Dapsone and Their Hydroxylamine Metabolites[NCT00000826] | Phase 1 | 48 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
43 reviews available for dapsone and Pneumonia, Pneumocystis
| Article | Year |
|---|---|
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
Topics: Animals; Drug Design; Humans; Immunosuppression Therapy; Molecular Structure; Opportunistic Infectio | 1995 |
Dapsone for Pneumocystis jirovecii pneumonia prophylaxis - applying theory to clinical practice with a focus on drug interactions.
Topics: Antifungal Agents; Azoles; Dapsone; Dose-Response Relationship, Drug; Drug Interactions; Humans; Pne | 2020 |
Diagnosis and management of Pneumocystis jirovecii infection.
Topics: Antifungal Agents; beta-Glucans; Biomarkers; Dapsone; Disease Management; Humans; Incidence; L-Lacta | 2017 |
A short history of dapsone, or an alternative model of drug development.
Topics: Antimalarials; Dapsone; Drug Industry; History, 20th Century; Humans; Leprostatic Agents; Leprosy; M | 2011 |
[Prophylaxis against Pneumocystis pneumonia in pediatric and adult patients undergoing solid organ or hematopoietic stem cells transplantation].
Topics: Adult; Anti-Infective Agents; Child; Dapsone; Drug Administration Schedule; Evidence-Based Medicine; | 2012 |
Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance.
Topics: Anti-Infective Agents; Dapsone; Dihydropteroate Synthase; Drug Resistance, Fungal; Gene Expression; | 2004 |
Pneumocystis carinii pneumonia treatment in people infected with HIV.
Topics: Antifungal Agents; Atovaquone; Clindamycin; Dapsone; Drug Therapy, Combination; HIV Infections; Huma | 2004 |
Pneumocystis pneumonia in people with HIV.
Topics: Atovaquone; Clindamycin; Corticosterone; Dapsone; Drug Therapy, Combination; HIV Infections; Humans; | 2005 |
Pneumocystis pneumonia in people with HIV.
Topics: Anti-Infective Agents; Antiprotozoal Agents; Atovaquone; Clindamycin; Dapsone; Drug Therapy, Combina | 2006 |
A background and critical analysis of the treatment of pneumocystis carinii pneumonia (PCP) in HIV/AIDS.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Anti-Inflammatory Agents; Antiprotozoa | 2007 |
Hyperkalemia and high-dose trimethoprim/sulfamethoxazole.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Dapsone; Drug Therapy, Combination; Hu | 1995 |
Human immunodeficiency virus infection in children.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Dapsone; Didanosine; Dru | 1995 |
[Current alternatives in the treatment of Pneumocystis carinii pneumonia in patients with AIDS].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Atovaquone; Clindamycin; Dapsone; Eflornit | 1994 |
A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
Topics: AIDS-Related Opportunistic Infections; Dapsone; Dose-Response Relationship, Drug; Humans; Logistic M | 1996 |
Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; | 1995 |
[Therapy and prevention of pneumocystis carinii pneumonia].
Topics: AIDS-Related Opportunistic Infections; Animals; Antifungal Agents; Atovaquone; Clindamycin; Clinical | 1995 |
Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Ag | 1996 |
Recent advances in the prevention of pneumocystis carinii pneumonia.
Topics: Aerosols; Child; Dapsone; Humans; Pentamidine; Pneumonia, Pneumocystis; Pyrimethamine; Trimethoprim, | 1996 |
Treatment of Pneumocystis carinii pneumonia in adults with AIDS.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifunga | 1997 |
Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Topics: Administration, Inhalation; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal | 1997 |
Methemoglobinemia associated with dapsone treatment in solid organ transplant recipients: a two-case report and review.
Topics: Aged; Dapsone; Female; Humans; Kidney Transplantation; Liver Transplantation; Methemoglobinemia; Mid | 1997 |
Prevention of community-acquired and nosocomial pneumonia.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacterial Vaccines; Community-Acquired Infections; Cross I | 1996 |
Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation.
Topics: Anti-Infective Agents; Bone Marrow Transplantation; Child, Preschool; Dapsone; Disease Susceptibilit | 1997 |
Prevention of infection due to Pneumocystis carinii.
Topics: Animals; Antibiotic Prophylaxis; Antifungal Agents; Atovaquone; Clindamycin; Dapsone; Fungal Vaccine | 1998 |
Dapsone-induced methemoglobinemia.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Dapsone; Female; Humans; Methemoglobinemia; Pne | 1998 |
Treatment of infection due to Pneumocystis carinii.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Atovaquone; Clindamycin; Dapsone; Eflornithine; Humans | 1998 |
Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Clinical Trials as To | 1998 |
Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Antifungal Agents; Atovaquone; Clinical Trials as To | 1998 |
[Effect of dapsone on survival in HIV infected patients: a meta- analysis of finished trials].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Anti-Inflammatory Agents, Non-S | 2000 |
[Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].
Topics: Adolescent; Age Factors; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infectiv | 2001 |
The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Hypersensitivity; Humans; Male; Opportunist | 1992 |
Prophylaxis of AIDS-related opportunistic infections (OIs). Current status and future strategies.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Animals; Cryptococcosis; Cytomegalovirus Infections; D | 1991 |
[Pneumocystis carinii pneumonia in HIV infection. Diagnosis, prognostic factors and curative treatment].
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; CD4-Positive T-Lymphocytes; Dapsone; Eflornithine; F | 1991 |
Prophylaxis and treatment of Pneumocystis carinii pneumonia.
Topics: Antimalarials; CD4-Positive T-Lymphocytes; Clinical Protocols; Dapsone; Drug Combinations; HIV Infec | 1991 |
Pneumocystis carinii: a deadly opportunist.
Topics: Biopsy; Bronchoalveolar Lavage Fluid; Bronchoscopy; Clinical Protocols; Dapsone; Decision Trees; Dia | 1991 |
[Pneumocystis carinii pneumonia in HIV infections. Committee of the 1st Consensus Conference of anti-infectious therapy organized in May 1990 in Paris by the Société de Pathologie Infectieuse de Langue Française].
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Clinical Protocols; Dapsone; France; HIV Infections; H | 1990 |
[Consensus conference: pneumocystosis in HIV infections. 1st consensus conference in anti-infection therapeutics organized by "la Société de Pathologie Infectieuse de langue française", May 11, 1990].
Topics: Adrenal Cortex Hormones; Dapsone; France; HIV Infections; Humans; Opportunistic Infections; Pentamid | 1990 |
Recent developments in the therapy and management of Pneumocystis carinii pneumonia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Therapy, Combination; Humans; Pentamidine; Pneumon | 1989 |
Prophylaxis of AIDS-related opportunistic infections (OIs).
Topics: Acquired Immunodeficiency Syndrome; Cryptococcosis; Cytomegalovirus Infections; Dapsone; Drug Combin | 1989 |
Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: pathophysiology, therapy, and prevention.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Dapsone; Diet; Drug Combinations; Humans; Oxygen Inhal | 1989 |
Pneumocystis carinii pneumonia: therapy and prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Dapsone; Drug Combinations; Drug Therapy, | 1988 |
Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Antiprotozoal Agents; Clinical Trials a | 1988 |
Prevention of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Dapsone; Drug Combinations; Humans; Pentamidine; Pneum | 1988 |
44 trials available for dapsone and Pneumonia, Pneumocystis
| Article | Year |
|---|---|
Pharmacokinetics of dapsone in human immunodeficiency virus-infected children.
Topics: Aging; Anti-Infective Agents; Child; Child, Preschool; Dapsone; Female; Half-Life; HIV Infections; H | 1995 |
Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aerosols; AIDS-Related Opportunistic Infections; Dapsone; | 1995 |
Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Dapsone; Drug Administration Schedule; Drug Ther | 1995 |
Dapsone/pyrimethamine may prevent mycobacterial disease in immunosuppressed patients infected with the human immunodeficiency virus.
Topics: Adult; CD4 Lymphocyte Count; Dapsone; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Huma | 1995 |
Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
Topics: Administration, Inhalation; Adult; AIDS-Related Opportunistic Infections; Animals; Dapsone; Drug Adm | 1995 |
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
Topics: Administration, Oral; Adult; Aerosols; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; | 1995 |
Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.
Topics: Adult; AIDS-Related Opportunistic Infections; Biological Availability; Chromatography, High Pressure | 1994 |
Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Adult; Aerosols; AIDS-Related Opportunistic Infections; Dapsone; Encephalitis; Female; Humans; Male; | 1993 |
Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Combination; Female; Follow-Up | 1994 |
Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
Topics: Adult; Aerosols; AIDS-Related Opportunistic Infections; Antifungal Agents; Dapsone; Drug Therapy, Co | 1993 |
Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals.
Topics: Adult; AIDS-Related Opportunistic Infections; Contraindications; Dapsone; Drug Eruptions; Female; Fe | 1993 |
The relative efficacy of oral dapsone and nebulized pentamidine as prophylaxis for Pneumocystis carinii pneumonia.
Topics: Administration, Oral; Aerosols; Dapsone; Humans; Nebulizers and Vaporizers; Pentamidine; Pneumonia, | 1993 |
Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
Topics: Adult; AIDS-Related Complex; AIDS-Related Opportunistic Infections; Dapsone; Drug Combinations; Ence | 1993 |
Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Administration Schedule; Drug Therapy, C | 1993 |
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infe | 1995 |
Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Clindamycin; Dapsone; Double-Blind Met | 1996 |
Alternative dapsone dosage regimen for prophylaxis of Pneumocystis carinii pneumonia.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiviral Agents; Child; Child, Presch | 1996 |
Low-dose dapsone, co-trimoxazole, and survival in Pneumocystis carinii primary prophylaxis.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Drug Therapy, Combination; Hu | 1996 |
Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Analysis of Variance; Anti-Infective Agents; Antibioti | 1996 |
Penetration of dapsone into pulmonary lining fluid of human immunodeficiency virus type 1-infected patients.
Topics: Adult; Bronchoalveolar Lavage Fluid; Bronchoscopy; Chromatography, High Pressure Liquid; Dapsone; Fe | 1997 |
Penetration of dapsone into cerebrospinal fluid of patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Female; Humans; Male; Middle Aged; Pneumonia, Pn | 1997 |
Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Analysis of Variance; Anti-Infective Agent | 1998 |
Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Grou
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Atovaquone; Dapsone; Female; Fo | 1998 |
A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Infecti | 1997 |
Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia.
Topics: Adult; AIDS-Related Opportunistic Infections; Analysis of Variance; Anti-Infective Agents; Area Unde | 1999 |
Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Child; Child, Preschool; Dapsone; Drug | 1999 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children.
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Chromatography, High Pressure Liquid; Da | 1999 |
Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Dihydropteroate Synthase; Female; Humans; Male; | 2000 |
Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial.
Topics: Adult; Animals; Anti-Infective Agents; Bacterial Infections; Dapsone; Encephalitis; Female; HIV Infe | 2001 |
Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antibiotics, Antitubercula | 2001 |
Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia.
Topics: Dapsone; Drug Therapy, Combination; HIV Infections; Humans; Pneumonia, Pneumocystis; Pyrimethamine; | 1992 |
Co-trimoxazole versus dapsone-pyrimethamine for prevention of Pneumocystis carinii pneumonia.
Topics: Adult; CD4-Positive T-Lymphocytes; Dapsone; Drug Administration Schedule; Female; Humans; Leukocyte | 1992 |
[Successful treatment of HIV-associated pneumocystis carinii pneumonia with dapsone plus trimethoprim].
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Ambulatory Care; Dapsone; Dose-R | 1992 |
Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity.
Topics: Administration, Intranasal; Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Bloo | 1992 |
Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia.
Topics: Adult; Dapsone; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infec | 1992 |
Prophylaxis of AIDS-related opportunistic infections (OIs). Current status and future strategies.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Animals; Cryptococcosis; Cytomegalovirus Infections; D | 1991 |
Low-dose co-trimoxazole, aerosolised pentamidine, or dapsone plus pyrimethamine for prevention of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Follow-Up Studies; Humans; Pentamidine; Pneumonia, Pneu | 1991 |
Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Dapsone; Drug Administration Schedule; Hum | 1990 |
Dapsone as a single agent is suboptimal therapy for Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Humans; Male; Pneumonia, Pneumocystis; Prospecti | 1991 |
Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Chemical and Drug Induced Liver Inj | 1990 |
Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions.
Topics: Acetylation; Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Interactions; Drug Therapy, Co | 1989 |
Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Antiprotozoal Agents; Clinical Trials a | 1988 |
Pneumocystis carinii pneumonia in the patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Bronchoscopy; Clinical Trials as Topic; Dapsone; Drug C | 1985 |
130 other studies available for dapsone and Pneumonia, Pneumocystis
| Article | Year |
|---|---|
Bad luck comes in threes.
Topics: Anemia, Hemolytic; Dapsone; Humans; Methemoglobinemia; Pneumonia, Pneumocystis | 2023 |
High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antilymphocyte Serum; Atovaquone; CD4 Lymphocyte Cou | 2020 |
Methemoglobinemia in Transplant Recipient Patients: Future of Dapsone as
Topics: Anti-Infective Agents; Dapsone; Humans; Methemoglobinemia; Organ Transplantation; Pneumocystis carin | 2020 |
Murphy's law in force: sequential adverse events encountered during the treatment of Pneumocystis pneumonia (cotrimoxazole-induced acute peripheral neuropathy and primaquine-induced methemoglobinemia).
Topics: Anti-Bacterial Agents; Antimalarials; Clindamycin; Dapsone; Drug Therapy, Combination; Female; Human | 2020 |
Dapsone-induced methemoglobinemia in pediatrics post-renal transplant.
Topics: Anti-Infective Agents; Child; Dapsone; Female; Humans; Kidney Transplantation; Male; Methemoglobinem | 2021 |
Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Topics: Aged; Anemia, Hemolytic; Anti-Infective Agents; Antibiotic Prophylaxis; Dapsone; Female; Hematologic | 2018 |
Advantages of dapsone over trimethoprim/sulfamethoxazole for Pneumocystis pneumonia prophylaxis in patients with immunobullous disease.
Topics: Dapsone; Humans; Pneumonia, Pneumocystis; Skin Diseases; Trimethoprim, Sulfamethoxazole Drug Combina | 2021 |
Dapsone, 2 birds with 1 stone: A response to "Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients".
Topics: Animals; Anti-Infective Agents; Birds; Dapsone; Humans; Pneumonia, Pneumocystis; Trimethoprim, Sulfa | 2021 |
Response: Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients.
Topics: Anti-Infective Agents; Dapsone; Drug Therapy, Combination; Humans; Pneumonia, Pneumocystis; Trimetho | 2021 |
Dapsone-Induced Methemoglobinemia in Two Renal Transplant Recipients.
Topics: Aged; Anti-Infective Agents; Dapsone; Enzyme Inhibitors; Female; Humans; Kidney Failure, Chronic; Ki | 2019 |
Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; AIDS-Related Opportunistic Infections; Anti-Infec | 2013 |
Dapsone-induced methemoglobinemia in renal transplant recipients: more prevalent than previously thought.
Topics: Adult; Aged; Anti-Infective Agents; Azathioprine; Cohort Studies; Cyclosporine; Dapsone; Female; Glo | 2014 |
A short history of dapsone, or an alternative model of drug development.
Topics: Antimalarials; Antitubercular Agents; Dapsone; History, 20th Century; Humans; Leprostatic Agents; Le | 2011 |
An audit of dapsone-associated methaemoglobinaemia in renal transplant recipients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Dapsone; Female; Humans; Kidney Transplantati | 2014 |
Identifying the Cause of the "Saturation Gap": Two Cases of Dapsone-induced Methemoglobinemia.
Topics: Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Cryptogenic Organizing Pneumonia; | 2015 |
Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation.
Topics: Anti-Infective Agents; Cohort Studies; Dapsone; Humans; Immunosuppressive Agents; Kidney Transplanta | 2015 |
Lower Extremity Edema, Anxiety, and Cyanosis During Chemoradiation Therapy for Glioblastoma.
Topics: Anti-Infective Agents; Anxiety; Brain Neoplasms; Chemoradiotherapy; Cyanosis; Dapsone; Edema; Female | 2016 |
Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Atovaquone; Child; Child, Preschool; Dapsone; Fem | 2016 |
High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Caspofungin; Chil | 2017 |
Efficacy and Safety of Dapsone Versus Trimethoprim/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia.
Topics: Antibiotic Prophylaxis; Child; Child, Preschool; Dapsone; Female; Humans; Infant; Male; Neutropenia; | 2017 |
Innovative use of dapsone.
Topics: Adult; Anti-Infective Agents; Autoimmune Diseases; Child; Dapsone; Humans; Hypersensitivity; Jaundic | 2010 |
Dapsone-associated methaemoglobinaemia in patients with a haematologic malignancy.
Topics: Adult; Aged; Anti-Infective Agents; Dapsone; Female; Hematologic Neoplasms; Humans; Male; Methemoglo | 2010 |
Dapsone-induced methemoglobinemia: a dose-related occurrence?
Topics: Anemia, Aplastic; Anti-Infective Agents; Child; Child, Preschool; Cohort Studies; Cross-Sectional St | 2011 |
Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia, Hemolytic; Anti-HIV Agents; Anti-Infective Age | 2012 |
Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Asia; CD4 Lymphocy | 2012 |
Two cases of acquired methemoglobinemia.
Topics: Anti-Infective Agents; Antidotes; Dapsone; Female; HIV Infections; HIV-1; Humans; Male; Methemoglobi | 2012 |
Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Bronchoalveolar Lavage Fluid; Dapsone; | 2003 |
Reinstituting trimethoprim--sulfamethoxazole in patients receiving atovaquone for Pneumocystis carinii pneumonia prophylaxis.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Atovaquone; Clinical Protocols; Dapson | 2003 |
Use of dapsone in the treatment of Pneumocystis carinii pneumonia in a foal.
Topics: Animals; Anti-Infective Agents; Dapsone; Diarrhea; Horse Diseases; Horses; Male; Pneumocystis carini | 2004 |
Dapsone-induced hypersensitivity pneumonitis mimicking Pneumocystis carinii pneumonia in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alveolitis, Extrinsic Allergic; Dapsone; Diagnosis, Diffe | 2004 |
Increase in prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and China.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Age | 2004 |
Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels.
Topics: Anti-Infective Agents; Case-Control Studies; Child; Child, Preschool; Cytochrome-B(5) Reductase; Dap | 2005 |
Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients.
Topics: Adult; Aged; Anemia, Hemolytic; Anti-Infective Agents; Antibiotic Prophylaxis; Dapsone; Female; Huma | 2005 |
Safe discontinuation of primary pneumocystis prophylaxis in Southern Indian HIV-infected patients on highly active antiretroviral therapy.
Topics: Anti-Infective Agents; Anti-Retroviral Agents; Antiprotozoal Agents; Antiretroviral Therapy, Highly | 2005 |
Adverse reactions associated with dapsone therapy in HIV-positive patients: a case presentation and review.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Drug Hypersensitivity; | 2006 |
The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation.
Topics: Anemia, Hemolytic; Chemical and Drug Induced Liver Injury; Dapsone; Dermatitis, Exfoliative; Drug Hy | 2006 |
Methemoglobinemia associated with dapsone therapy in a child with pneumonia and chronic immune thrombocytopenic purpura.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Mur | 2006 |
Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.
Topics: Animals; Dapsone; Disease Models, Animal; Drug Combinations; Male; Pneumonia, Pneumocystis; Rats; Ra | 1984 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
Prevention and treatment of Pneumocystis carinii pneumonia in patients infected with HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Combination; Fees, Pharmaceutic | 1994 |
A case of atypical cyanosis.
Topics: Adult; Cyanosis; Dapsone; Humans; Male; Methemoglobinemia; Pneumonia, Pneumocystis | 1995 |
Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
Topics: Adult; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Dapsone; HIV Infections; HIV-1; | 1995 |
Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice.
Topics: Animals; Antifungal Agents; Atovaquone; Dapsone; Drug Therapy, Combination; Mice; Mice, SCID; Naphth | 1995 |
High failure rate of dapsone and pentamidine as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected children.
Topics: Child, Preschool; Dapsone; HIV Infections; Humans; Infant; Male; Pneumonia, Pneumocystis; Trimethopr | 1994 |
Primary prophylaxis against opportunistic infections in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Clotrimazole; Dapsone; Fluconazole; Humans; Mycoses; Pentamid | 1995 |
Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Candidiasis; CD4-Positive | 1993 |
Persistence of Pneumocystis carinii in patients with AIDS receiving chemoprophylaxis.
Topics: Adult; AIDS-Related Opportunistic Infections; Bronchoalveolar Lavage Fluid; Dapsone; Humans; Male; M | 1994 |
Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Chemical and Drug Induced Liver Injury; Dapsone; Drug | 1994 |
Adverse reactions to dapsone in persons infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Tolerance; Humans; Male; Pneumonia, Pneumoc | 1994 |
Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Adult; Aged; Dapsone; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Phenotyp | 1994 |
Does drug interaction cause failure of PCP prophylaxis with dapsone?
Topics: Dapsone; Didanosine; Drug Interactions; HIV Infections; Humans; Pneumonia, Pneumocystis; Retrospecti | 1993 |
Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Clindamycin; Dapso | 1994 |
Dapsone for prevention of Pneumocystis pneumonia in children with acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Child; Dapsone; Female; Humans; Infant; Pneumonia, Pne | 1994 |
Dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children.
Topics: Child; Child, Preschool; Dapsone; HIV Infections; Humans; Infant; Pneumonia, Pneumocystis | 1994 |
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Topics: AIDS-Related Opportunistic Infections; Animals; Dapsone; Disease Models, Animal; Dose-Response Relat | 1993 |
Population-based estimates of antiretroviral therapy and anti-Pneumocystis prophylaxis in San Francisco: 1991.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiviral Agents; Cohort Studies; Daps | 1993 |
Efficacy and safety of dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Dapsone; Humans; Infant; | 1993 |
Failure of intravenous pentamidine prophylaxis for Pneumocystis carinii pneumonia.
Topics: Administration, Inhalation; Aerosols; AIDS-Related Opportunistic Infections; Child, Preschool; Dapso | 1993 |
Comparing Pneumocystis carinii pneumonia prophylactic regimens.
Topics: Dapsone; Humans; Pneumonia, Pneumocystis; Research Design; Trimethoprim, Sulfamethoxazole Drug Combi | 1993 |
Hepatic and pulmonary pneumocystosis during primary prophylaxis for Pneumocystis carinii pneumonia with dapsone/pyrimethamine.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Combination; Humans; Liver Dise | 1993 |
Systemic Pneumocystis carinii pneumonia prophylaxis with dapsone and pyrimethamine fails to protect against extrapulmonary pneumocystosis.
Topics: Administration, Inhalation; Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Com | 1993 |
Predictive value of bronchoalveolar lavage in excluding a diagnosis of Pneumocystis carinii pneumonia during prophylaxis with aerosolized pentamidine.
Topics: Administration, Intranasal; Adult; Aerosols; AIDS-Related Opportunistic Infections; Bronchoalveolar | 1993 |
Pyrimethamine inhibits renal secretion of creatinine.
Topics: Adult; Creatinine; Dapsone; Drug Administration Schedule; Drug Interactions; Female; Humans; Kidney; | 1993 |
Prophylaxis of pneumocystis pneumonia and toxoplasmosis.
Topics: Anti-Infective Agents; Dapsone; Drug Therapy, Combination; Humans; Pneumonia, Pneumocystis; Pyrimeth | 1996 |
Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxalate for secondary prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Da | 1996 |
Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole.
Topics: Adult; Anti-Infective Agents; Anti-Infective Agents, Urinary; Dapsone; Dose-Response Relationship, D | 1996 |
Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; Bronchoalveo | 1996 |
Adverse events from drug therapy for human immunodeficiency virus disease.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dapsone; Didanosine; Female; HIV Infections; Humans; | 1996 |
Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia, Hemolytic; Anti-Infective Agents; Clindamycin; | 1996 |
[Dapsone in the prevention of HIV-related parasitosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiparasitic Agents; Dapsone; Drug Therapy, Combinati | 1996 |
Does dapsone increase mortality when given for prophylaxis of Pneumocystis carinii pneumonia?
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Humans; Pneumonia, Pneumocyst | 1996 |
Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; CD4 Lymphocyte Count; Clindamyci | 1996 |
Dapsone penetrates cerebrospinal fluid during Pneumocystis carinii pneumonia prophylaxis.
Topics: Adult; Anti-Infective Agents; Dapsone; Humans; Pneumonia, Pneumocystis | 1996 |
Penetration of dapsone into lung of human immunodeficiency virus-infected children.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Bronchoalveolar Lavage Fluid; Bronchos | 1997 |
How to interpret an overview: a meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Clinical Trials as Topic; Dapsone; Dat | 1997 |
Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Amino Acid Sequence; Anti-Infective | 1998 |
Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators.
Topics: Adult; AIDS-Related Opportunistic Infections; Ambulatory Care; Anti-Infective Agents; Antifungal Age | 1998 |
Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Algorithms; Anti-HIV Agen | 1998 |
Successful desensitization to dapsone for Pneumocystis carinii prophylaxis in an HIV-positive patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Desensitization, Immun | 1998 |
Bilateral upper-lobe cavitary Pneumocystis carinii pneumonia in a patient on dapsone prophylaxis.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Diagnosis, Differential; Huma | 1999 |
Atovaquone compared with dapsone to prevent Pneumocystis carinii pneumonia.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Atovaquone; Dapsone; Drug Costs; HIV I | 1999 |
Reasons for failure of prophylaxis for Pneumocystis carinii pneumonia.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; Dapsone; Humans; Pe | 1999 |
Drug-resistant Pneumocystis carinii.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Dihydropteroate Synthase; Dru | 1999 |
Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use.
Topics: Amino Acid Sequence; Animals; Anti-Infective Agents; Cloning, Molecular; Dapsone; Dihydropteroate Sy | 1999 |
High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis.
Topics: Adult; Anti-Infective Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Cohort Studies; | 1999 |
Blue and breathless.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dapsone; Fatal Outcome; Female; HIV Seropositivity; | 1999 |
Unusual presentation of thoracic Pneumocystis carinii infection in a patient with acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Biopsy; Dapsone; Diagnosis, Dif | 2001 |
Quantifying and documenting prior beliefs in clinical trials.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; Atovaquone; Attitud | 2001 |
Dapsone/pyrimethamine versus aerosolized pentamidine as prophylaxis against PCP in HIV infection.
Topics: Adult; Aerosols; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents | 1995 |
Current management practices in the treatment of Pneumocystis carinii pneumonia (PCP).
Topics: AIDS-Related Opportunistic Infections; Algorithms; Anti-Infective Agents; Antifungal Agents; Dapsone | 1996 |
Preventing opportunistic infections.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Clarithromycin; Clindamycin; Clinical Trials as To | 1995 |
PCP prevention for children.
Topics: Antifungal Agents; Atovaquone; Clinical Trials as Topic; Dapsone; HIV Infections; Infant; Infant, Ne | 1995 |
Optimizing PCP therapy.
Topics: Aerosols; AIDS-Related Opportunistic Infections; Antifungal Agents; Atovaquone; CD4 Lymphocyte Count | 1997 |
Adherence to PCP medications found to be low.
Topics: AIDS-Related Opportunistic Infections; Dapsone; Humans; Patient Compliance; Pneumonia, Pneumocystis; | 1998 |
[A clinical study of six cases of Pneumocystis carinii pneumonia].
Topics: Acute Disease; Adult; Aged; Anemia, Hemolytic, Autoimmune; Anti-Infective Agents; Dapsone; Female; H | 1998 |
Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Dihydropteroate Syntha | 2001 |
Immunohematotoxicity studies with combinations of dapsone and zidovudine.
Topics: AIDS-Related Opportunistic Infections; Anemia; Animals; Anti-HIV Agents; Antiprotozoal Agents; Bone | 2001 |
Pneumocystis carinii dihydropteroate synthase mutations and treatment with sulfa or sulfone regimens: a proposal for standardized definitions for clinical evaluation.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Dapsone; Dihydropteroate Synthase; Humans; Mutation; | 2001 |
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiprotozoal Agents; Atovaquone; CD4 | 2002 |
Failure of pentamidine isethionate to provide chemoprophylaxis against Pneumocytis carinii infection in rats.
Topics: Animals; Dapsone; Lung; Male; Pneumocystis; Pneumonia, Pneumocystis; Rats | 1975 |
Drug interactions in use of dapsone for Pneumocystis carinii prophylaxis.
Topics: Dapsone; Drug Interactions; HIV Infections; Humans; Pneumonia, Pneumocystis; Rifampin | 1992 |
Significance of drug interactions with rifampin in Pneumocystis carinii pneumonia prophylaxis.
Topics: Dapsone; Drug Interactions; Humans; Pneumonia, Pneumocystis; Rifampin | 1992 |
New developments in the treatment of Pneumocystis carinii pneumonia.
Topics: Adrenal Cortex Hormones; Aerosols; Dapsone; Drug Therapy, Combination; Eflornithine; Folic Acid Anta | 1992 |
A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Dapsone; Drug Administration Schedule; Drug Therapy | 1992 |
Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus.
Topics: Aerosols; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Clinical Protocols; Dapsone; Drug Adm | 1991 |
From the Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus.
Topics: Aerosols; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Clinical Protocols; Dapsone; Drug Adm | 1991 |
Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Antiviral Agents; CD4-Positive T-Lymphocytes; Cost-Ben | 1991 |
Adverse reactions to co-trimoxazole in HIV infection.
Topics: Cytochrome P-450 Enzyme System; Dapsone; HIV Seropositivity; Humans; Opportunistic Infections; Pneum | 1991 |
Respiratory insufficiency from dapsone-induced methemoglobinemia.
Topics: Adult; Dapsone; HIV Infections; Humans; Male; Methemoglobinemia; Opportunistic Infections; Pneumonia | 1991 |
Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis.
Topics: Acquired Immunodeficiency Syndrome; Brain Diseases; Dapsone; Drug Administration Schedule; Drug Ther | 1991 |
Inhaled pentamidine and prevention of Pneumocystis pneumonia.
Topics: Administration, Inhalation; Cost-Benefit Analysis; Dapsone; Humans; Pentamidine; Pneumonia, Pneumocy | 1991 |
Failure of prophylaxis with dapsone in patients taking dideoxyinosine.
Topics: Dapsone; Didanosine; Humans; Pneumonia, Pneumocystis | 1991 |
Dapsone in low doses prevents Pneumocystis carinii pneumonia in the rat model.
Topics: Administration, Oral; Animals; Dapsone; Diet; Disease Models, Animal; Immune Tolerance; Male; Pneumo | 1991 |
Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; AIDS-Related Complex; Costs and Cos | 1990 |
Megaloblastic pancytopenia associated with dapsone and trimethoprim treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Anemia, Macrocytic; Anemia, Megaloblastic; Dapsone; Humans; Leuc | 1990 |
Primary dapsone chemoprophylaxis for Pneumocystis carinii pneumonia in immunocompromised patients infected with the human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; AIDS-Related Complex; Dapsone; Huma | 1989 |
Pneumocystis carinii pneumonia in Stockholm, Sweden: treatment, outcome, one-year-follow-up and pyrimethamine prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Dapsone; Drug Evaluation; Drug Therapy, Combination | 1989 |
[Treatment and prevention of pneumocystosis].
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Anti-Bacterial Agents; Dapsone; Humans; | 1989 |
Megaloblastic pancytopenia associated with dapsone and trimethoprim treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Therapy, Combination; Humans; Male; Pancyto | 1989 |
Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Bronchoscopy; Dapsone; Drug Eruptions; Drug Therapy, Combination | 1986 |
Treatment of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Combinations; Folic Acid Antagonists; Humans; Meth | 1987 |
Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Adult; Anti-Infective Agents; Dapsone; | 1988 |
Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Dapsone; Diminazene; Disease Models, Animal; Drug Com | 1988 |
Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.
Topics: Animals; Dapsone; Drug Therapy, Combination; Folic Acid Antagonists; Immunosuppression Therapy; Male | 1988 |
Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.
Topics: Amidines; Animals; Anti-Infective Agents; Dapsone; Drug Administration Schedule; Drug Combinations; | 1988 |
Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Dapsone; Drug Therapy, Combination; Humans; M | 1988 |
AIDS-related Pneumocystis carinii pneumonia successfully treated with dapsone-trimethoprim.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Therapy, Combination; Humans; Male; Pneumon | 1988 |
Successful treatment and prevention of murine Pneumocystis carinii pneumonitis with 4,4'-sulfonylbisformanilide.
Topics: Animals; Dapsone; Dexamethasone; Drug Combinations; Pneumonia, Pneumocystis; Rats; Sulfamethoxazole; | 1986 |
Dapsone-induced methemoglobinemia in a patient with P. carinii pneumonia and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Humans; Male; Methemoglobinemia; Pneumonia, Pneumocysti | 1987 |
Dapsone, trimethoprim-sulfamethoxazole, and the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Combinations; Humans; Pneumonia, Pneumocystis; Sul | 1985 |